📊 GUTS Key Takeaways
Is Fractyl Health, Inc.. (GUTS) a Good Investment?
Fractyl Health exhibits terminal financial distress with zero revenue, $141M net losses, and $90.9M negative free cash flow. Despite a $81.5M cash position providing 12 months of runway, the company has fundamentally failed to commercialize its medical device platform and faces insolvency without immediate turnaround or capital infusion. No visible path to profitability or revenue recovery.
Fractyl Health is pre-revenue with very large operating and net losses, yielding extremely negative ROA/ROE and no visibility into unit economics. Liquidity is currently solid with substantial cash and no debt, but the burn rate implies roughly a year of runway and a high likelihood of additional capital needs. Until there is clear progress toward commercialization and operating leverage, the fundamental profile remains weak.
Why Buy Fractyl Health, Inc.. Stock? GUTS Key Strengths
- Positive cash balance of $81.5M provides near-term runway
- Strong liquidity ratios (4.78x current ratio) with minimal current liabilities
- Zero long-term debt eliminates refinancing risk
- Strong liquidity (current ratio ~4.8x; $81.5M cash)
- Debt-free balance sheet reducing insolvency risk
- Low capex intensity provides expense flexibility
GUTS Stock Risks: Fractyl Health, Inc.. Investment Risks
- Complete revenue collapse (100% YoY decline to $0) indicates failed commercialization
- Severe cash burn of $90.9M annually will deplete reserves within 12 months at current rate
- Operating losses of $96.8M and net losses of $141M demonstrate unprofitable core business
- Stockholders' equity only $9.5M (9% of assets) - minimal equity cushion before insolvency
- Medical device sector clinical/regulatory risks with no offsetting commercial success
- Pre-revenue status with no demonstrated commercial traction
- High cash burn likely necessitating dilutive financing
- Very small equity base and deeply negative ROA/ROE
Key Metrics to Watch
- Monthly cash burn rate and remaining runway before capital requirement
- Revenue recognition from any source (commercialization progress or partnerships)
- Gross margin trends if revenue returns (current $43K insufficient for analysis)
- Quarterly operating cash flow (cash burn) and runway
- Quarterly revenue and gross margin upon launch
Fractyl Health, Inc.. (GUTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.78x current ratio provides a solid financial cushion.
GUTS Profit Margin, ROE & Profitability Analysis
GUTS vs Healthcare Sector: How Fractyl Health, Inc.. Compares
How Fractyl Health, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fractyl Health, Inc.. Stock Overvalued? GUTS Valuation Analysis 2026
Based on fundamental analysis, Fractyl Health, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fractyl Health, Inc.. Balance Sheet: GUTS Debt, Cash & Liquidity
GUTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fractyl Health, Inc..'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-1.62 indicates the company is currently unprofitable.
GUTS Revenue Growth, EPS Growth & YoY Performance
GUTS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.0K | -$3.3M | $-0.48 |
| Q2 2025 | $43.0K | -$3.3M | $-0.36 |
| Q1 2025 | $33.0K | -$3.3M | $-0.17 |
| Q3 2024 | $14.0K | -$3.3M | $-0.48 |
| Q2 2024 | $43.0K | -$3.3M | $-0.36 |
| Q1 2024 | $5.0K | -$3.3M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fractyl Health, Inc.. Dividends, Buybacks & Capital Allocation
GUTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fractyl Health, Inc.. (CIK: 0001572616)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GUTS
What is the AI rating for GUTS?
Fractyl Health, Inc.. (GUTS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GUTS's key strengths?
Claude: Positive cash balance of $81.5M provides near-term runway. Strong liquidity ratios (4.78x current ratio) with minimal current liabilities. ChatGPT: Strong liquidity (current ratio ~4.8x; $81.5M cash). Debt-free balance sheet reducing insolvency risk.
What are the risks of investing in GUTS?
Claude: Complete revenue collapse (100% YoY decline to $0) indicates failed commercialization. Severe cash burn of $90.9M annually will deplete reserves within 12 months at current rate. ChatGPT: Pre-revenue status with no demonstrated commercial traction. High cash burn likely necessitating dilutive financing.
What is GUTS's revenue and growth?
Fractyl Health, Inc.. reported revenue of $0.0.
Does GUTS pay dividends?
Fractyl Health, Inc.. does not currently pay dividends.
Where can I find GUTS SEC filings?
Official SEC filings for Fractyl Health, Inc.. (CIK: 0001572616) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GUTS's EPS?
Fractyl Health, Inc.. has a diluted EPS of $-1.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GUTS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fractyl Health, Inc.. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GUTS stock overvalued or undervalued?
Valuation metrics for GUTS: ROE of -1,490.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GUTS stock in 2026?
Our dual AI analysis gives Fractyl Health, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GUTS's free cash flow?
Fractyl Health, Inc..'s operating cash flow is $-90.3M, with capital expenditures of $557.0K.
How does GUTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -1,490.3% (avg: 15%), current ratio 4.78 (avg: 2).